A Phase 4 interventional study of Clomiphene Citrate. and Pioglitazone (PIO) + Clomiphene citrate in Infertility Treatment and Pregnancy Rates, sponsored by PAEC General Hospital, Islamabad. Recruiting at 1 site in Pakistan. Open to female participants aged 18 Years to 38 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-03-10.
Sponsored by PAEC General Hospital, Islamabad · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies testing clomiphene in Infertility — 1 open to participants now, 4 under way, 1 of them phase 3. Clomiphene · Infertility.
Among the 33 studies testing clomiphene in Infertility, this one is the 22nd largest by planned enrollment, is the only one that started in 2026, is one of 19 in phase 4, and was the 32nd registered.
2,090 studies on the registry are indexed under Infertility; 355 are open to participants now.
Browse Infertility studies →1 of the 33 studies testing clomiphene in Infertility is open now, in 1 country.
By country, each count listing its studies:
Clomiphene: first FDA approval 1967 (CLOMID). What it is approved for, and how studies give it, is on its page →
Of the 232 Infertility studies recruiting now, 43 (19%) set no upper age limit and 183 (79%) stop at 75 or younger; 27 take children under 18; 74 take healthy volunteers.
This study: 18 Years to 38 Years · female · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 1 · Phase 2 2 · Phase 3 6 · Phase 4 19
First in 1991; this study’s year is marked. 1 started in 2026.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 62 is below the median of 133 across 1,415 interventional studies indexed under Infertility.
Median enrollment 154 across the 33 interventional studies. Of the 18 that completed or were terminated, 6 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 33 have an industry lead sponsor. The 10 most frequent:
PAEC General Hospital, Islamabad is the lead sponsor of 9 studies on the registry; 5 are open to participants now.
PAEC General Hospital, Islamabad has 1 study filed under Infertility — fewer than ten, so there is no comparison to draw.
None of the studies under way reaches primary completion within a year.
Among the 33 studies testing clomiphene in Infertility, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Women who meet the study requirements will be enrolled and randomly assigned by a computer system to receive either pioglitazone 30 mg daily or a placebo starting from the second day of their menstrual period for the same duration. All participants will also take clomiphene citrate 150 mg daily from day 3 to day 7 of the menstrual cycle. A transvaginal ultrasound will be performed on day 10 of the menstrual cycle to assess the growth of ovarian follicles, and the number of mature follicles (16-24 mm) will be recorded. If at least one mature follicle measuring 16-24 mm is present and the endometrial thickness is at least 7 mm, an injection of human chorionic gonadotropin (hCG) will be given to trigger ovulation, followed by an intrauterine insemination (IUI) procedure. Participants will be followed until the end of the menstrual cycle, and if the menstrual period is delayed by 5 days, a blood test for β-hCG will be performed to confirm pregnancy. Any side effects during the treatment period, such as swelling, fluid retention, blurred vision, or weight gain, will be recorded.
Patients fulfilling the inclusion criteria will be enrolled and randomized using computer-generated random numbers to receive either pioglitazone 30 mg daily or a placebo starting from the second day of menstruation for a similar duration. All participants will receive clomiphene citrate 150 mg between the third and seventh days of the menstrual cycle. Transvaginal sonography will be performed on the 10th day of the menstrual cycle, and the number of large follicles (16-24 mm) will be recorded. Human chorionic gonadotropin (hCG) will be administered to patients with at least one follicle measuring 16-24 mm and an endometrial thickness of at least 7 mm, followed by intrauterine insemination (IUI). Patients will be followed until the end of the menstrual cycle, and in cases of a 5-day delay in menstruation, a blood sample will be obtained to measure β-hCG for biochemical confirmation of pregnancy. Any adverse effects observed during the treatment period, including edema, fluid retention, blurred vision, or weight gain, will be documented.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Normal hysterosalpingography Normal spermogram Suffering from PCOS Ovarian cysts less than 20mm.
Exclusion Criteria:
History of chronic cardiovascular disease Chronic kidney disease Diabetes Thyroid disease Pulmonary disease
Drug: Clomiphene Citrate.
Drug: Pioglitazone (PIO) + Clomiphene citrate
150 mg clomiphene citrate will be administered at third and seventh days of the menstrual cycle
Drug pages: PioglitazoneStudies of PioglitazonePioglitazone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record. · ClomipheneStudies of ClomipheneClomiphene pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.
Patients will receive 30 mg pioglitazone daily; from the second day of menstruation along with 150 mg clomiphene citrate will be administered to both groups between the third and seventh days of the menstrual cycle.
Ovarian stimulation rate
This will be determined by no. of large size follicles (16-24mm in size) recruited following treatment on 10th day of menstrual cycle using transvaginal ultrasound to measure the size and no. of follicles.
Time frame: 10th day of menstrual cycle
Pregnancy rates
It will be measured in terms of number of patients out of total number treated who conceived. This will be confirmed clinically as well as by measuring serum bHCG levels if patient doesn't not menstruate for more than 5 days following end of her reproductive cycle.
Time frame: 5th day after end of menstrual cycle
Plan to share: No — Ethical committee doesnt allow data sharing
Started Mar 2026 (actual). Primary completion is estimated for Jun 2026, 3 months after the start.
Of 74 non-industry phase 4 interventional studies under Infertility, half reached primary completion within 34 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 82. This study's planned 3 months is below that.
Counting every sponsor, half of 81 studies reached it within 33 months; a quarter within 19 and three quarters within 82.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Pioglitazone · Clomiphene
PAEC General Hospital, Islamabad